1.1. Analysis.
Comparison 1 Subcutaneous omalizumab + steroid versus placebo + steroid (stable steroid), Outcome 1 Number of participants with at least one exacerbation (ICS and OCS users).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.